28,300 Shares in Celcuity, Inc. $CELC Bought by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd bought a new position in Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 28,300 shares of the company’s stock, valued at approximately $2,960,746,000. Celcuity accounts for approximately 2.3% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 13th biggest holding.

Several other hedge funds have also added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its stake in shares of Celcuity by 20.1% during the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after buying an additional 86 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after acquiring an additional 124 shares during the last quarter. US Bancorp DE boosted its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the period. Intech Investment Management LLC boosted its holdings in Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after acquiring an additional 183 shares during the period. Finally, Aristides Capital LLC grew its position in Celcuity by 2.0% during the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after acquiring an additional 303 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Guggenheim lifted their price target on Celcuity from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Wall Street Zen lowered shares of Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Needham & Company LLC lowered their price target on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Stock Down 2.9%

Shares of NASDAQ:CELC opened at $90.79 on Tuesday. The stock’s 50-day moving average is $94.28 and its 200 day moving average is $107.55. The company has a market cap of $4.44 billion, a PE ratio of -21.11 and a beta of 0.21. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity, Inc. has a 1 year low of $44.42 and a 1 year high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Sell-side analysts anticipate that Celcuity, Inc. will post -4.51 EPS for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.